Clearmind Medicine Inc. said the United States Patent and Trademark Office published its patent application covering a combination of MDMA and N-acylethanolamines, including palmitoylethanolamide, for treating post-traumatic stress disorder, anxiety and eating disorders.
The company, which trades on the NASDAQ under the ticker CMND, said the patent application describes how PEA may enhance MDMA’s therapeutic potency, reduce required dosing and mitigate side effects. Clearmind added that the combination therapy is designed to improve outcomes in patients with conditions that currently have limited treatment options.
The announcement follows the U.S. Food and Drug Administration’s finalization of guidance on psychedelic drugs on July 13, which includes MDMA in its definition of psychedelics alongside classic compounds. The FDA’s guidance outlines recommendations for trial design, subject safety, data collection and new drug application requirements, citing challenges posed by psychoactive effects and alterations in mood, cognition and perception.
Clearmind’s intellectual property portfolio now comprises 19 patent families, including 32 granted patents, with the company noting that its collaboration with NeuroThera Labs Inc. has generated 13 patent applications globally. Clearmind’s shares trade on the NASDAQ and NeuroThera’s on the TSX Venture Exchange under the ticker NTLX.
The patent application was published by the USPTO on August 24, 2026.
